Skip to main content
HairCited

Minoxidil per Alopecia areata

A Evidenze Più grandi trial clinici mostrano in modo costante benefici significativi.

Basato su 48 studi (2 meta-analyses, 1 RCT) con 21,842 partecipanti totali. 37/48 studi mostrano effetti positivi.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dalopecia\u002Dareata'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

In sintesi

Minoxidil has strong evidence supporting its use for alopecia areata, with the majority of studies showing positive effects, and is widely used as both a topical and oral option for this condition.

  • 37 out of 48 studies show positive effects across a large pool of 21,842 participants
  • Available in topical (2% and 5%) and oral low-dose formulations
  • Extends the hair growth phase and increases blood supply to hair follicles
  • Often used in combination with other treatments like corticosteroids for enhanced effectiveness

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: women with androgenetic alopecia (female pattern hair loss)

Case Reports n=1
Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case …
Dose: None vs: None Outcome: hair regrowth in severe alopecia areata Effetto: None None

Popolazione: patient with severe alopecia areata with suboptimal response to tofacitinib

review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 vs: Placebo Effetto: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2% None
Randomized Controlled Trial n=150 12 weeks
Fractional CO2 Laser and Minoxidil in the Treatment of Alopecia Areata, A Comparative Study.
Dose: Topical minoxidil 5% solution vs: Topical saline (control, n=30) Outcome: Hair growth improvement grade Effetto: 80% excellent (combo) vs 53% excellent (minox only) None

Popolazione: Patients with alopecia areata (n=150)

review
The Use of Light-Based Therapies in the Treatment of Alopecia.
Dose: Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri vs: Placebo Effetto: LLLT improves hair density in AGA; potential to prolong anagen phase in telogen effluvium; may promo None
retrospective cohort study n=321
Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study.
Dose: Minoxidil (OTC) and clobetasol for mild cases; prescription medications for moderate-severe. Specifi vs: Placebo Effetto: 91.3% received definitive remote diagnosis; only 8.7% required in-person follow-up. AA most common ( None

Key Statistics

122

Studi

27416

Partecipanti

Positive

A

Grado

Referenced Papers

Dermatologic clinics 2025 5 citazioni
Pediatric dermatology 2025 5 citazioni
Journal of the … 2025 2 citazioni
International journal of … 2025 1 citazioni
Journal of clinical … 2025 1 citazioni
Archives of dermatological … 2025
International journal of … 2024 39 citazioni
American family physician 2024 8 citazioni
Skin health and … 2024 7 citazioni
Journal of the … 2024 7 citazioni
The Journal of … 2024 2 citazioni
Archives of dermatological … 2023 16 citazioni
The Cochrane database … 2023 2 citazioni
The Journal of … 2022 170 citazioni
Journal of the … 2022 90 citazioni
Dermatology and therapy 2022 43 citazioni
Skin appendage disorders 2022 7 citazioni
The American Journal … 2022 2 citazioni
Journal of dermatological … 2021 51 citazioni
American journal of … 2020 127 citazioni
International journal of … 2020 58 citazioni
The journal of … 2020 3 citazioni
The Australasian journal … 2019 152 citazioni
American journal of … 2019 84 citazioni
Journal of the … 2019 50 citazioni
Expert opinion on … 2019 34 citazioni
Journal of drugs … 2019 20 citazioni
Klinicka onkologie : … 2019 11 citazioni
Journal of the … 2018 114 citazioni
Dermatology online journal 2018
American family physician 2017 141 citazioni
American journal of … 2017 32 citazioni
Actas dermo-sifiliograficas 2017 17 citazioni
Deutsches Arzteblatt international 2016 99 citazioni
Current problems in … 2015 322 citazioni
The Medical clinics … 2015 66 citazioni
Canadian family physician … 2015 31 citazioni
The journal of … 2015 25 citazioni
Current problems in … 2015 18 citazioni
Der Internist 2015
Lasers in surgery … 2014 243 citazioni
American journal of … 2014 82 citazioni
Expert opinion on … 2014 57 citazioni
Giornale italiano di … 2014 18 citazioni
Giornale italiano di … 2014
International journal of … 2013 61 citazioni
Recent patents on … 2011 6 citazioni
Seminars in cutaneous … 2009 85 citazioni
American family physician 2009
The Cochrane database … 2008 222 citazioni
Current opinion in … 2008 31 citazioni
International journal of … 2007 185 citazioni
Alopecia areata. Case Report
Dermatology nursing 2007
The Australasian journal … 2006
Journal of the … 2005 44 citazioni
Cleveland Clinic journal … 2005
Praxis 2003 28 citazioni
American family physician 2003 2 citazioni
American family physician 2003
American journal of … 2000 28 citazioni
International journal of … 1999 16 citazioni
Dermatologic clinics 1998 121 citazioni
American family physician 1990
Dermatologic clinics 1987
Journal of the … 1984 122 citazioni
Journal of the … 1984
Archives of dermatology 1984

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

topical:
2-5% solution, twice daily

Limite massimo: 5% topical solution

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Neutral --
None -- Positive 1
Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 -- Positive --
Topical minoxidil 5% solution 12 weeks Positive 150
Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri -- Positive --
Minoxidil (OTC) and clobetasol for mild cases; prescription medications for moderate-severe. Specifi -- Positive 321
None -- Mixed --
None -- Mixed 1

Momento migliore per l'assunzione: Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

Effetti collaterali segnalati

  • Scalp irritation and dryness
  • Initial shedding phase (first 2-8 weeks)
  • Unwanted facial hair growth (especially in women)
  • Dizziness or lightheadedness (rare with topical use)
  • Heart palpitations (rare, more common with oral form)

Interazioni note

  • Antihypertensive medications (additive blood pressure lowering)
  • Topical corticosteroids (may increase absorption)
  • Retinoids (tretinoin may enhance penetration and side effects)

Livello di assunzione massimo tollerabile: 5% topical solution

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Minoxidil help with Alopecia areata?
Based on 122 studies with 27,416 participants, there is strong evidence from multiple clinical trials that Minoxidil may support Alopecia areata management. Our evidence grade is A (Strong Evidence).
How much Minoxidil should I take for Alopecia areata?
Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Minoxidil?
Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Minoxidil and Alopecia areata?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 122 peer-reviewed studies with 27,416 total participants. The overall direction of effect is positive.

References

  1. [1] Michael M Ong et al.. Am J Clin Dermatol. 2026. Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations. doi:10.1007/s40257-025-00990-4 PubMed
  2. [2] Caitlin A Kearney et al.. Am J Clin Dermatol. 2026. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. doi:10.1007/s40257-026-01009-2 PubMed
  3. [3] Zulin Wan et al.. Front Immunol. 2026. Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review. doi:10.3389/fimmu.2026.1766847 PubMed
  4. [4] Eric McMullen et al.. Int J Dermatol. 2026. Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review. doi:10.1111/ijd.70194 PubMed
  5. [5] Jair Alejandro Valdez-Zertuche et al.. Expert Opin Drug Metab Toxicol. 2025. Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review. doi:10.1080/17425255.2025.2461483 PubMed
  6. [6] Yozahandy A Abarca et al.. Cureus. 2025. Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities. doi:10.7759/cureus.78298 PubMed
  7. [7] Sarah Schaffer et al.. Cureus. 2025. A Scoping Review of Exosome Delivery Applications in Hair Loss. doi:10.7759/cureus.81152 PubMed
  8. [8] Luiza Kalil et al.. Dermatol Clin. 2025. Innovation in Alopecia Areata. doi:10.1016/j.det.2024.09.001 PubMed
  9. [9] Luiza Kalil et al.. Pediatr Dermatol. 2025. Systemic Therapies for Pediatric Alopecia Areata. doi:10.1111/pde.15822 PubMed
  10. [10] Kailyn Valido et al.. J Am Acad Dermatol. 2025. Baricitinib and oral minoxidil for the treatment of alopecia areata in pediatric patients. doi:10.1016/j.jaad.2025.03.085 PubMed
  11. [11] Rui Wang et al.. Drug Dev Res. 2025. A Novel Topical Compound Gel Loading Minoxidil and Tofacitinib for Treatment of Alopecia Areata: Formulation, Characterization, and In Vitro/In Vivo … doi:10.1002/ddr.70076 PubMed
  12. [12] Luiza Kalil et al.. J Am Acad Dermatol. 2025. Oral minoxidil treatment of alopecia areata. doi:10.1016/j.jaad.2025.05.1446 PubMed
  13. [13] Xuexue Pan et al.. Aesthetic Plast Surg. 2025. Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation. doi:10.1007/s00266-025-05077-3 PubMed
  14. [14] Rui-Xian Guo et al.. Front Pharmacol. 2025. Research progress in the treatment of non-scarring alopecia: mechanism and treatment. doi:10.3389/fphar.2025.1544068 PubMed
  15. [15] Kailyn Valido et al.. J Am Acad Dermatol. 2025. Combination oral minoxidil and baricitinib treatment of alopecia areata. doi:10.1016/j.jaad.2025.05.1393 PubMed
  16. [16] Farheen Begum et al.. Indian Dermatol Online J. 2025. Comparison of Safety and Efficacy of Topical Mometasone 0.1% Ointment, Calcipotriol 0.005% Ointment, and Tacrolimus 0.1% Ointment in Patients with … doi:10.4103/idoj.idoj_913_23 PubMed
  17. [17] Carli D Needle et al.. Int J Dermatol. 2025. Alopecia Treatments in Breastfeeding: Safety and Clinical Considerations. doi:10.1111/ijd.17940 PubMed
  18. [18] Ana Melián-Olivera et al.. J Clin Med. 2025. Frontal Fibrosing Alopecia in Men: A Review of the Literature. doi:10.3390/jcm14061914 PubMed
  19. [19] Esraa Elsayed Elhawary et al.. Lasers Surg Med. 2025. Fractional CO2 Laser and Minoxidil in the Treatment of Alopecia Areata, A Comparative Study. doi:10.1002/lsm.23876 PubMed
  20. [20] Alondra Saray Polanco-Llanes et al.. Cureus. 2025. Plica Neuropathica (Polonica) Secondary to Diffuse Alopecia: A Case Report and Literature Review. doi:10.7759/cureus.93402 PubMed
  21. [21] Robert J Vanaria et al.. J Cosmet Dermatol. 2025. The Use of Light-Based Therapies in the Treatment of Alopecia. doi:10.1111/jocd.70434 PubMed
  22. [22] Juan Jimenez-Cauhe et al.. J Am Acad Dermatol. 2025. Combination of oral minoxidil and baricitinib for alopecia areata: A retrospective study of 77 patients. doi:10.1016/j.jaad.2025.10.157 PubMed
  23. [23] Carli D Needle et al.. Arch Dermatol Res. 2025. Key considerations of injectable minoxidil for alopecia. doi:10.1007/s00403-025-04068-3 PubMed
  24. [24] Aliyyat Afolabi et al.. Telemed Rep. 2025. Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study. doi:10.1177/26924366251366793 PubMed
  25. [25] Adam Leavitt et al.. J Drugs Dermatol. 2025. Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions. doi:10.36849/JDD.8763 PubMed
  26. [26] L Rudnicka et al.. J Eur Acad Dermatol Venereol. 2024. European expert consensus statement on the systemic treatment of alopecia areata. doi:10.1111/jdv.19768 PubMed
  27. [27] Dan Liu et al.. Int J Med Sci. 2024. Status of research on the development and regeneration of hair follicles. doi:10.7150/ijms.88508 PubMed
  28. [28] Mohammad Amin Jafari et al.. Health Sci Rep. 2024. Efficacy and Safety of Laser Therapy and Phototherapy in Cicatricial and NonCicatricial Alopecia: A Systematic Review Study. doi:10.1002/hsr2.70180 PubMed
  29. [29] Eliza Balazic et al.. Lasers Med Sci. 2024. The role of laser and energy-assisted drug delivery in the treatment of alopecia. doi:10.1007/s10103-024-04015-0 PubMed
  30. [30] Linnea L Westerkam et al.. Paediatr Drugs. 2024. Treatment Options for Alopecia Areata in Children and Adolescents. doi:10.1007/s40272-024-00620-2 PubMed
  31. [31] Michał Majewski et al.. J Clin Med. 2024. The Role of Minoxidil in Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis. doi:10.3390/jcm13247712 PubMed
  32. [32] MaryAnn Dakkak et al.. Am Fam Physician. 2024. Hair Loss: Diagnosis and Treatment. PubMed
  33. [33] Ramadan S Hussein et al.. Skin Health Dis. 2024. Applications and efficacy of minoxidil in dermatology. doi:10.1002/ski2.472 PubMed
  34. [34] Ruchi S Raval et al.. J Am Acad Dermatol. 2024. The use of minoxidil in the treatment of alopecia areata: A systematic review. doi:10.1016/j.jaad.2024.05.037 PubMed
  35. [35] Aarushi K Parikh et al.. Life (Basel). 2024. Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia. doi:10.3390/life14121577 PubMed
  36. [36] Fanglin Wei et al.. Skin Res Technol. 2024. Effect of minoxidil combined with triamcinolone acetonide on alopecia areata by microneedle injection. doi:10.1111/srt.13713 PubMed
  37. [37] Anjum Muhammad et al.. Cureus. 2024. Comparison of Efficacy of Autologous Platelet Rich Plasma Therapy With 5% Topical Minoxidil Spray in Treating Alopecia Areata: A Head-to-Head … doi:10.7759/cureus.61878 PubMed
  38. [38] Rabia Ghafoor et al.. J Coll Physicians Surg Pak. 2024. The Role of 5% Minoxidil <em>versus</em> Platelet-Rich Plasma in Treatment of Alopecia Areata. doi:10.29271/jcpsp.2024.06.650 PubMed
  39. [39] Yutong Xie et al.. J Dermatolog Treat. 2024. Cosmetic filler-induced hair loss: case series and literature review. doi:10.1080/09546634.2024.2443111 PubMed
  40. [40] Sana Aslam et al.. Cureus. 2024. Comparison of Efficacy of Topical Betamethasone Dipropionate and Topical Minoxidil in Patients With Alopecia Areata. doi:10.7759/cureus.56282 PubMed
  41. [41] Chenqi Guo et al.. J Dermatolog Treat. 2024. Efficacy and safety of compound glycyrrhizin combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized … doi:10.1080/09546634.2024.2381766 PubMed
  42. [42] Brittany Feaster et al.. Arch Dermatol Res. 2023. Oral minoxidil use in androgenetic alopecia and telogen effluvium. doi:10.1007/s00403-022-02331-5 PubMed
  43. [43] Breno N Matos et al.. Pharmaceuticals (Basel). 2023. Follicle-Targeted Delivery of Betamethasone and Minoxidil Co-Entrapped in Polymeric and Lipid Nanoparticles for Topical Alopecia Areata Treatment. doi:10.3390/ph16091322 PubMed
  44. [44] Jianfeng Zhang et al.. Lasers Med Sci. 2023. Laser and light therapy combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized controlled trials. doi:10.1007/s10103-023-03734-0 PubMed
  45. [45] Michelle Fuschlberger et al.. Sci Rep. 2023. Vitamin B12 supplementation and health behavior of Austrian vegans: a cross-sectional online survey. doi:10.1038/s41598-023-30843-1 PubMed
  46. [46] Rita Fernanda Cortez de Almeida et al.. Skin Appendage Disord. 2023. Scalp Microinfusion: A Novel Drug Delivery Technique for Hair Loss Treatment. doi:10.1159/000528446 PubMed
  47. [47] S Cedirian et al.. J Cosmet Dermatol. 2023. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic … doi:10.1111/jocd.15873 PubMed
  48. [48] Michela Starace et al.. Ital J Dermatol Venerol. 2023. Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic … doi:10.23736/S2784-8671.22.07416-3 PubMed
  49. [49] Daranporn Triwongwaranat et al.. Medicine (Baltimore). 2023. Characteristics of hair loss in COVID-19 patients in Thailand. doi:10.1097/MD.0000000000036539 PubMed
  50. [50] Ji Won Lee et al.. J Dermatol. 2023. Hair loss after drug reaction with eosinophilia and systemic symptoms (DRESS): A multicentric retrospective case series. doi:10.1111/1346-8138.16715 PubMed
  51. [51] Yuqing Shen et al.. J Cosmet Dermatol. 2023. Effect of fractional laser alone or in combination on alopecia areata: A systematic review and meta-analysis. doi:10.1111/jocd.15630 PubMed
  52. [52] Miriam Mateos-Haro et al.. Cochrane Database Syst Rev. 2023. Treatments for alopecia areata: a network meta-analysis. doi:10.1002/14651858.CD013719.pub2 PubMed
  53. [53] Monica Păun et al.. Medicina (Kaunas). 2023. Epidemiologic Study of Gene Distribution in Romanian and Brazilian Patients with Non-Cicatricial Alopecia. doi:10.3390/medicina59091654 PubMed
  54. [54] A K Gupta et al.. J Dermatolog Treat. 2022. Minoxidil: a comprehensive review. doi:10.1080/09546634.2021.1945527 PubMed
  55. [55] Virginia R Barton et al.. J Am Acad Dermatol. 2022. Treatment of pediatric alopecia areata: A systematic review. doi:10.1016/j.jaad.2021.04.077 PubMed
  56. [56] Robert S English et al.. Dermatol Ther (Heidelb). 2022. Microneedling and Its Use in Hair Loss Disorders: A Systematic Review. doi:10.1007/s13555-021-00653-2 PubMed
  57. [57] Talagavadi Channaiah Anudeep et al.. Pharmaceutics. 2022. Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia. doi:10.3390/pharmaceutics14030612 PubMed
  58. [58] Dong Wook Shin. Korean J Physiol Pharmacol. 2022. The physiological and pharmacological roles of prostaglandins in hair growth. doi:10.4196/kjpp.2022.26.6.405 PubMed
  59. [59] Belen de Nicolas-Ruanes et al.. J Am Acad Dermatol. 2022. Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study. doi:10.1016/j.jaad.2022.04.030 PubMed
  60. [60] Manabu Ohyama et al.. J Dermatol. 2022. Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better … doi:10.1111/1346-8138.16475 PubMed
  61. [61] Mahmoud Abd El-Rahim Abdallah et al.. J Dermatolog Treat. 2022. Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata. doi:10.1080/09546634.2020.1793893 PubMed
  62. [62] Fabrizio Martora et al.. Skin Appendage Disord. 2022. Oral Minoxidil for Chemotherapy-Induced Alopecia. doi:10.1159/000525463 PubMed
  63. [63] Samir Kumar Praharaj et al.. Hum Psychopharmacol. 2022. Valproate-associated hair abnormalities: Pathophysiology and management strategies. doi:10.1002/hup.2814 PubMed
  64. [64] Dalia Mahmoud Toma et al.. Dermatol Ther. 2022. Comparative study between topical methotrexate 1% gel and minoxidil 5% gel in the treatment of localized alopecia areata. doi:10.1111/dth.15696 PubMed
  65. [65] Elizabeth Klein et al.. J Drugs Dermatol. 2022. Reversible Hair Loss in Lichen Planopilaris: Regrowth With Low-Dose Naltrexone and Platelet-Rich Plasma. doi:10.36849/JDD.6810 PubMed
  66. [66] Ronan Talty et al.. JAAD Case Rep. 2022. Sisaipho alopecia areata treated with tofacitinib and oral minoxidil. doi:10.1016/j.jdcr.2022.08.037 PubMed
  67. [67] Danchen Hu et al.. Am J Dermatopathol. 2022. Rare Concurrence of Alopecia Areata in the Setting of the Lipedematous Scalp. doi:10.1097/DAD.0000000000002261 PubMed
  68. [68] Mark S Nestor et al.. J Cosmet Dermatol. 2021. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. doi:10.1111/jocd.14537 PubMed
  69. [69] Cheng Zhou et al.. Clin Rev Allergy Immunol. 2021. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. doi:10.1007/s12016-021-08883-0 PubMed
  70. [70] Michael Randolph et al.. J Am Acad Dermatol. 2021. Oral minoxidil treatment for hair loss: A review of efficacy and safety. doi:10.1016/j.jaad.2020.06.1009 PubMed
  71. [71] A Sterkens et al.. Clin Exp Med. 2021. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. doi:10.1007/s10238-020-00673-w PubMed
  72. [72] Carlos G Wambier et al.. J Am Acad Dermatol. 2021. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. doi:10.1016/j.jaad.2019.08.080 PubMed
  73. [73] A Villani et al.. J Eur Acad Dermatol Venereol. 2021. Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. doi:10.1111/jdv.17216 PubMed
  74. [74] Masoumeh Roohaninasab et al.. Dermatol Ther. 2021. Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability. doi:10.1111/dth.14768 PubMed
  75. [75] Ginny Oong Chien Yin et al.. J Dermatol Sci. 2021. Telogen Effluvium - a review of the science and current obstacles. doi:10.1016/j.jdermsci.2021.01.007 PubMed
  76. [76] Bevin Bhoyrul et al.. JAMA Dermatol. 2021. Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors. doi:10.1001/jamadermatol.2021.3676 PubMed
  77. [77] Takeshi Fukumoto et al.. Dermatol Ther. 2021. Treatments for alopecia areata: A systematic review and network meta-analysis. doi:10.1111/dth.14916 PubMed
  78. [78] Michela Starace et al.. Am J Clin Dermatol. 2020. Female Androgenetic Alopecia: An Update on Diagnosis and Management. doi:10.1007/s40257-019-00479-x PubMed
  79. [79] Ajay N Sharma et al.. Int J Dermatol. 2020. Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. doi:10.1111/ijd.14933 PubMed
  80. [80] Chauncey C Barbulescu et al.. J Invest Dermatol. 2020. Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata. doi:10.1016/j.jid.2019.03.1142 PubMed
  81. [81] Kam L Hon et al.. Recent Pat Inflamm Allergy Drug Discov. 2020. Childhood Alopecia Areata: An Overview of Treatment and Recent Patents. doi:10.2174/1872213X14999200728145822 PubMed
  82. [82] Maria K Hordinsky. J Investig Dermatol Symp Proc. 2020. Current Treatment of Alopecia Areata. doi:10.1016/j.jisp.2020.04.004 PubMed
  83. [83] William C Cranwell et al.. Australas J Dermatol. 2019. Treatment of alopecia areata: An Australian expert consensus statement. doi:10.1111/ajd.12941 PubMed
  84. [84] Jenna R Stoehr et al.. Am J Clin Dermatol. 2019. Off-Label Use of Topical Minoxidil in Alopecia: A Review. doi:10.1007/s40257-018-0409-y PubMed
  85. [85] P C B Freire et al.. J Eur Acad Dermatol Venereol. 2019. Minoxidil for patchy alopecia areata: systematic review and meta-analysis. doi:10.1111/jdv.15545 PubMed
  86. [86] Jorge Ocampo-Garza et al.. Expert Opin Investig Drugs. 2019. New drugs under investigation for the treatment of alopecias. doi:10.1080/13543784.2019.1568989 PubMed
  87. [87] Calvin T. Sung et al.. J Drugs Dermatol. 2019. The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review. PubMed
  88. [88] Angela Wipf et al.. J Cosmet Laser Ther. 2019. The rise of transcutaneous drug delivery for the management of alopecia: a review of existing literature and an eye towards … doi:10.1080/14764172.2018.1525743 PubMed
  89. [89] Eduardo Anitua et al.. J Cosmet Dermatol. 2019. Platelet rich plasma for the management of hair loss: Better alone or in combination? doi:10.1111/jocd.12683 PubMed
  90. [90] Hana Jedličková et al.. Klin Onkol. 2019. Alopecia and Hair Damage Induced by Oncological Therapy. doi:10.14735/amko2019353 PubMed
  91. [91] Lauren C Strazzulla et al.. J Am Acad Dermatol. 2018. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. doi:10.1016/j.jaad.2017.04.1142 PubMed
  92. [92] R M Fertig et al.. J Eur Acad Dermatol Venereol. 2018. Microneedling for the treatment of hair loss? doi:10.1111/jdv.14722 PubMed
  93. [93] Bu Young Choi. Int J Mol Sci. 2018. Hair-Growth Potential of Ginseng and Its Major Metabolites: A Review on Its Molecular Mechanisms. doi:10.3390/ijms19092703 PubMed
  94. [94] Erkin Pekmezci et al.. Med Arch. 2018. Proprietary Herbal Extract Downregulates the Gene Expression of IL-1α in HaCaT Cells: Possible Implications Against Nonscarring Alopecia. doi:10.5455/medarh.2018.72.136-140 PubMed
  95. [95] Ibrahim Najem et al.. J Cosmet Laser Ther. 2018. Use of low-level laser therapy in treatment of the androgenic alopecia, the first systematic review. doi:10.1080/14764172.2017.1400174 PubMed
  96. [96] A Gomez-Zubiaur et al.. Dermatol Online J. 2018. [Not Available]. PubMed
  97. [97] T Grant Phillips et al.. Am Fam Physician. 2017. Hair Loss: Common Causes and Treatment. PubMed
  98. [98] Moustafa A El Taieb et al.. Dermatol Ther. 2017. Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: A trichoscopic evaluation. doi:10.1111/dth.12437 PubMed
  99. [99] Marina Perper et al.. Lasers Med Sci. 2017. Efficacy of fractional lasers in treating alopecia: a literature review. doi:10.1007/s10103-017-2306-7 PubMed
  100. [100] Aditya K Gupta et al.. Am J Clin Dermatol. 2017. Treating Alopecia Areata: Current Practices Versus New Directions. doi:10.1007/s40257-016-0230-4 PubMed
  101. [101] S Vañó-Galván et al.. Actas Dermosifiliogr. 2017. New Treatments for Hair Loss. doi:10.1016/j.ad.2016.11.010 PubMed
  102. [102] Hans Wolff et al.. Dtsch Arztebl Int. 2016. The Diagnosis and Treatment of Hair and Scalp Diseases. doi:10.3238/arztebl.2016.0377 PubMed
  103. [103] Juliany Estefan et al.. Skinmed. 2016. Alopecia Areata-Part III: Prognosis and Treatment. PubMed
  104. [104] Eshini Perera et al.. Curr Probl Dermatol. 2015. Alopecia areata. doi:10.1159/000369406 PubMed
  105. [105] Jay C Vary. Med Clin North Am. 2015. Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. doi:10.1016/j.mcna.2015.07.003 PubMed
  106. [106] Frank Spano et al.. Can Fam Physician. 2015. Alopecia areata: Part 2: treatment. PubMed
  107. [107] Fernanda Torres et al.. Semin Cutan Med Surg. 2015. Female pattern alopecia and telogen effluvium: figuring out diffuse alopecia. doi:10.12788/j.sder.2015.0142 PubMed
  108. [108] Maria K Hordinsky. J Investig Dermatol Symp Proc. 2015. Current Treatments for Alopecia Areata. doi:10.1038/jidsymp.2015.41 PubMed
  109. [109] Rubina Alves et al.. Curr Probl Dermatol. 2015. Hair loss in children. doi:10.1159/000369405 PubMed
  110. [110] H Wolff. Internist (Berl). 2015. [Drug treatment of alopecia]. doi:10.1007/s00108-015-3763-3 PubMed
  111. [111] Pinar Avci et al.. Lasers Surg Med. 2014. Low-level laser (light) therapy (LLLT) for treatment of hair loss. doi:10.1002/lsm.22170 PubMed
  112. [112] Maria Hordinsky et al.. Am J Clin Dermatol. 2014. Alopecia areata: an evidence-based treatment update. doi:10.1007/s40257-014-0086-4 PubMed
  113. [113] Leyre Falto-Aizpurua et al.. Expert Opin Emerg Drugs. 2014. Emerging treatments in alopecia. doi:10.1517/14728214.2014.974550 PubMed
  114. [114] A Rebora. G Ital Dermatol Venereol. 2014. Telogen effluvium revisited. PubMed
  115. [115] A Rossi et al.. G Ital Dermatol Venereol. 2014. Treatment for alopecia. PubMed
  116. [116] Ingrid Herskovitz et al.. Int J Endocrinol Metab. 2013. Female pattern hair loss. doi:10.5812/ijem.9860 PubMed
  117. [117] Kam-Lun E Hon et al.. Recent Pat Inflamm Allergy Drug Discov. 2011. Alopecia areata. doi:10.2174/187221311795399291 PubMed
  118. [118] Seema Garg et al.. Semin Cutan Med Surg. 2009. Alopecia areata: evidence-based treatments. doi:10.1016/j.sder.2008.12.002 PubMed
  119. [119] Anne L Mounsey et al.. Am Fam Physician. 2009. Diagnosing and treating hair loss. PubMed
  120. [120] F M Delamere et al.. Cochrane Database Syst Rev. 2008. Interventions for alopecia areata. doi:10.1002/14651858.CD004413.pub2 PubMed
  121. [121] Laleh A Bedocs et al.. Curr Opin Pediatr. 2008. Adolescent hair loss. doi:10.1097/MOP.0b013e328305e285 PubMed
  122. [122] Dan Wasserman et al.. Int J Dermatol. 2007. Alopecia areata. doi:10.1111/j.1365-4632.2007.03193.x PubMed
  123. [123] Paul T Martinelli et al.. Dermatol Nurs. 2007. Alopecia areata. PubMed
  124. [124] Rhonda A Kwong et al.. Australas J Dermatol. 2006. Alopecia areata masquerading as frontal fibrosing alopecia. doi:10.1111/j.1440-0960.2006.00227.x PubMed
  125. [125] Patsy Lenane et al.. J Am Acad Dermatol. 2005. Congenital alopecia areata. doi:10.1016/j.jaad.2004.06.024 PubMed
  126. [126] Nicole C Dombrowski et al.. Cleve Clin J Med. 2005. Alopecia areata: what to expect from current treatments. doi:10.3949/ccjm.72.9.758 PubMed
  127. [127] R M Trüeb. Praxis (Bern 1994). 2003. [Hair loss]. doi:10.1024/0369-8394.92.36.1488 PubMed
  128. [128] C Carolyn Thiedke. Am Fam Physician. 2003. Alopecia in women. PubMed
  129. [129] Karyn Springer et al.. Am Fam Physician. 2003. Common hair loss disorders. PubMed
  130. [130] V M Meidan et al.. Drugs. 2001. Treatments for androgenetic alopecia and alopecia areata: current options and future prospects. doi:10.2165/00003495-200161010-00006 PubMed
  131. [131] A J Papadopoulos et al.. Am J Clin Dermatol. 2000. Alopecia areata. Pathogenesis, diagnosis, and therapy. doi:10.2165/00128071-200001020-00004 PubMed
  132. [132] M Sommer et al.. Int J Clin Pract. 1999. Therapeutic approaches to the management of common baldness. PubMed
  133. [133] J Shapiro et al.. Dermatol Clin. 1998. Hair regrowth. Therapeutic agents. doi:10.1016/s0733-8635(05)70017-6 PubMed
  134. [134] E L Khoury et al.. J Invest Dermatol. 1992. Topical minoxidil in alopecia areata: no effect on the perifollicular lymphoid infiltration. doi:10.1111/1523-1747.ep12611409 PubMed
  135. [135] E A Olsen et al.. Arch Dermatol. 1992. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. PubMed
  136. [136] J M Weitzner. Am Fam Physician. 1990. Alopecia areata. PubMed
  137. [137] S P Clissold et al.. Drugs. 1987. Topical minoxidil. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica. doi:10.2165/00003495-198733020-00002 PubMed
  138. [138] V C Fiedler-Weiss. Dermatol Clin. 1987. Minoxidil. PubMed
  139. [139] A J Mitchell et al.. J Am Acad Dermatol. 1984. Alopecia areata: pathogenesis and treatment. doi:10.1016/s0190-9622(84)80450-8 PubMed
  140. [140] E E Vanderveen et al.. J Am Acad Dermatol. 1984. Topical minoxidil for hair regrowth. doi:10.1016/s0190-9622(84)70183-6 PubMed
  141. [141] V C Weiss et al.. Arch Dermatol. 1984. Alopecia areata treated with topical minoxidil. PubMed

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.